Fibrin-selective thrombolytic therapy with recombinant staphylokinase.
Collen
D
D
Center for Molecular and Vascular Biology, University of Leuven, Belgium. desire.collen@med.kuleuven.ac.be
Vanderschueren
S
S
Van de Werf
F
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D002986:Clinical Trials as Topic; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005260:Female; D005337:Fibrin / Q000037:antagonists & inhibitors*; D005343:Fibrinolytic Agents / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D016056:Immunodominant Epitopes / Q000276:immunology; D008297:Male; D008666:Metalloendopeptidases / Q000235:genetics / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000188:drug therapy; D010215:Papio; D010865:Pilot Projects; D015202:Protein Engineering; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy*; D015912:Thrombolytic Therapy
D005343:Fibrinolytic Agents; D016056:Immunodominant Epitopes; D011994:Recombinant Proteins; D005337:Fibrin; D008666:Metalloendopeptidases; C022653:auR protein, Staphylococcus aureus